Immune to Cancer: The CRI Blog
-
Second Antibody FDA-Approved Against Multiple Myeloma
Elotuzumab (Empliciti) is the second antibody for myeloma approved in just two weeks.
-
Nivolumab Becomes First FDA-Approved Checkpoint Blockade for Kidney Cancer
New hope now exists for patients with advanced kidney cancer.
-
First Monoclonal Antibody for Multiple Myeloma Receives FDA Approval
Daratumumab (Darzalex®) is the first approved immunotherapy that targets CD38—a protein found in most multiple myeloma cells.